Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
GHK-Cu
Also known as: Copper Peptide, Glycyl-L-Histidyl-L-Lysine Copper
GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. Plasma levels decline significantly with age. It has extensive in vitro and animal data showing wound healing, collagen synthesis, anti-inflammatory, and antioxidant properties. Most human evidence is limited to topical dermatological applications.
Risk Level
Low RiskDifficulty
Beginner| CAS Number | 49557-75-7 |
| Molecular Formula | C14H23CuN6O4 |
| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Binds copper(II) ions and delivers them to tissues, activating collagen synthesis, glycosaminoglycan production, and growth factor expression. Modulates gene expression of over 4,000 genes, many involved in tissue remodeling. Suppresses NFkB-driven inflammation and activates antioxidant enzyme systems including superoxide dismutase.
Dosing Research
Topical: 1-2% cream applied daily. Subcutaneous (underground): 1-2 mg/day. Some protocols use 200 mcg injections at specific sites for localized tissue repair. Cycles of 4-8 weeks are common in underground use.
Side Effects & Risks
Topical use is well-tolerated with rare skin irritation. Systemic injection carries theoretical risks of copper toxicity with prolonged high-dose use. Injection site reactions and transient skin discoloration have been reported.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.